SEATTLE, May 5, 2015 /PRNewswire/ -- Omeros Corporation
(NASDAQ: OMER), a biopharmaceutical company committed to
discovering, developing and commercializing both small-molecule and
protein therapeutics for large-market as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system, today announced that the company will issue its
first quarter 2015 financial results for the period ended
March 31, 2015, on Monday, May 11, 2015, after market close. Omeros
management will host a conference call and webcast that day at
4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial
results.
Conference Call Details
To access the live conference
call via phone, please dial (844) 831-4029 from the United States and Canada or (920) 663-6278 internationally. The
participant passcode is 35820733. Please dial in approximately 10
minutes prior to the start of the call. A telephone replay will be
available for one week following the call and may be accessed by
dialing (855) 859-2056 from the United
States and Canada or (404)
537-3406 internationally. The replay passcode is 35820733.
To access the live and subsequently archived webcast of the
conference call, go to the Company's website at
www.omeros.com and go to "Events" under the Investors section
of the website. Please connect to the website at least 15 minutes
prior to the call to allow for any software download that may be
necessary.
About Omeros Corporation
Omeros is a biopharmaceutical
company committed to discovering, developing and commercializing
small-molecule and protein therapeutics for large-market as well as
orphan indications targeting inflammation, coagulopathies and
disorders of the central nervous system. Derived from its
proprietary PharmacoSurgery® platform, the company's first drug
product, Omidria™ (phenylephrine and ketorolac injection) 1%/0.3%,
has been approved by the FDA for use during cataract surgery or
intraocular lens (IOL) replacement to maintain pupil size by
preventing intraoperative miosis (pupil constriction) and to reduce
postoperative ocular pain. Omidria is currently under review for
marketing approval by the European Medicines Agency. Omeros has six
clinical-stage development programs focused on: complement-related
thrombotic microangiopathies; Huntington's disease, schizophrenia,
and cognitive impairment; addictive and compulsive disorders; and
preventing problems associated with surgical procedures. In
addition, Omeros has a proprietary GPCR platform, which is making
available an unprecedented number of new GPCR drug targets and
corresponding compounds to the pharmaceutical industry for drug
development.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/omeros-corporation-to-announce-first-quarter-2015-financial-results-on-may-11-2015-300077332.html
SOURCE Omeros Corporation